Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415382 | 1.00 | CHRNA7 (0.58) | CHRNA7NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL6413984 | 1.00 | CHRNA7 (0.58) | CHRNA7NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL6410984 | 0.88 | CHRNA7 (0.53) | CHRNA7NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL6417099 | 0.88 | CHRNA7 (0.53) | CHRNA7NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL6411628 | 0.88 | CHRNA7 (0.53) | CHRNA7NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL6417094 | 0.88 | CHRNA7 (0.53) | CHRNA7NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL6415025 | 0.88 | CHRNA7 (0.53) | CHRNA7NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL6410974 | 0.88 | CHRNA7 (0.53) | CHRNA7NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL6418058 | 0.85 | CHRNA7 (0.64) | CHRNA7KDM4EALDH1A1GAA | |
| SCHEMBL6418054 | 0.85 | CHRNA7 (0.64) | CHRNA7KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | claimed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC | 2005-09-29 | — | — | US | disclosed |
| US-6858613-B2 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PFIZER INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | CHRNA7 1475/4885NPC1 142/4885RAB9A 2031/4885 |
| US-20050215584-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | CHRNA7, UGT2B7, CHRNA5 | CHRNA7 1/4885NPC1 221/4885RAB9A 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.